Literature DB >> 34236778

The Heterogeneity of COPD Patients in a Community-Based Practice and the Inadequacy of the Global Initiative for Chronic Obstructive Lung Disease Criteria: A Real-World Experience.

Fortune O Alabi1, Hadaya A Alkhateeb1, Kayla M DeBarros1, Pierina S Barletti Benel1, Rachel L Sanchez-Martez1, Mia L Zeper1, Reema A Ismail1, Fred Umeh1, Nelson Medina-Villanueva1.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with differing clinical presentations, which range from an asymptomatic obstructive defect on spirometry to symptomatic normal spirometry. The current standard for diagnosis requires exposure history and the presence of an obstructive ventilatory defect (forced expiratory volume in 1 second [FEV1] to forced vital capacity [FVC] ratio < 70%) on spirometry. In this real-world study, we analyzed patients with physician-diagnosed COPD, described their characteristics, and evaluated the diagnostic sensitivity of Global initiative for chronic Obstructive Lung Disease (GOLD) criteria in this population.
METHODS: We retrospectively analyzed the charts of 2115 patients for eligibility. A total of 1224 patients with physician-diagnosed COPD were selected for this study. The average age was 68.4±11.5 years, with 51% being female. Of the 1224 patients, 18% did not have a history of smoking, 73% had bronchodilator testing, and a significant response of ≥12% was noted in 23% of the COPD patients. Moreover, 43% of the patients met the GOLD criteria for the diagnosis of COPD, whereas the Global Lung Function Initiative (GLI) and lower limit of normal (LLN)criteria were only able to identify 26%. DISCUSSION: COPD-related mortality is continuing to rise, and it is currently ranked as the third leading cause of death, globally, after cardiovascular diseases and strokes. Despite this alarming statistic, COPD diagnosis is delayed in most cases and can remain undiagnosed, even in smokers. This is partly due to the restrictive GOLD diagnostic criteria, which requires the presence of FEV1/FVC ratio<70.
CONCLUSIONS: The recently proposed COPD Genetic Epidemiology (COPDGene®) 2019 definition for COPD will improve and enhance our ability to diagnose COPD earlier and more accurately. JCOPDF
© 2021.

Entities:  

Keywords:  COPDGene; GOLD; chronic obstructive pulmonary disease; pulmonary function test; spirometry

Year:  2021        PMID: 34236778      PMCID: PMC8428596          DOI: 10.15326/jcopdf.2021.0229

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  29 in total

1.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

2.  Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study.

Authors:  Emily S Wan; John E Hokanson; James R Murphy; Elizabeth A Regan; Barry J Make; David A Lynch; James D Crapo; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

3.  Non-reversible airway obstruction in never smokers: results from the Austrian BOLD study.

Authors:  B Lamprecht; L Schirnhofer; B Kaiser; S Buist; M Studnicka
Journal:  Respir Med       Date:  2008-08-22       Impact factor: 3.415

4.  Susceptibility to exacerbation in COPD.

Authors:  John R Hurst; Antonio Anzueto; Jørgen Vestbo
Journal:  Lancet Respir Med       Date:  2017-09       Impact factor: 30.700

5.  Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.

Authors:  Yumin Zhou; Nan-Shan Zhong; Xiaochen Li; Shuyun Chen; Jinping Zheng; Dongxing Zhao; Weimin Yao; Rongchang Zhi; Liping Wei; Bingwen He; Xiangyan Zhang; Changli Yang; Ying Li; Fenglei Li; Juan Du; Jianping Gui; Bin Hu; Chunxue Bai; Ping Huang; Gang Chen; Yongjian Xu; Changzheng Wang; Biao Liang; Yinhuan Li; Guoping Hu; Hui Tan; Xianwei Ye; Xitao Ma; Yan Chen; Xiwei Hu; Jia Tian; Xiaodan Zhu; Zhe Shi; Xiufang Du; Minjing Li; Shengming Liu; Ronghuan Yu; Jianping Zhao; Qianli Ma; Canmao Xie; Xiongbin Li; Tao Chen; Yingxiang Lin; Lizhen Zeng; Changxiu Ye; Weishu Ye; Xiangwen Luo; Lingshan Zeng; Shuqing Yu; Wei-Jie Guan; Pixin Ran
Journal:  N Engl J Med       Date:  2017-09-07       Impact factor: 91.245

Review 6.  Global burden of COPD: systematic review and meta-analysis.

Authors:  R J Halbert; J L Natoli; A Gano; E Badamgarav; A S Buist; D M Mannino
Journal:  Eur Respir J       Date:  2006-04-12       Impact factor: 16.671

Review 7.  Chronic obstructive pulmonary disease in non-smokers.

Authors:  Sundeep S Salvi; Peter J Barnes
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

8.  Alpha 1-antitrypsin Pi-types in 965 COPD patients.

Authors:  J Lieberman; B Winter; A Sastre
Journal:  Chest       Date:  1986-03       Impact factor: 9.410

9.  "GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study".

Authors:  Gülmisal Güder; Susanne Brenner; Christiane E Angermann; Georg Ertl; Matthias Held; Alfred P Sachs; Jan-Willem Lammers; Pieter Zanen; Arno W Hoes; Stefan Störk; Frans H Rutten
Journal:  Respir Res       Date:  2012-02-06

10.  Low FVC/TLC in Preserved Ratio Impaired Spirometry (PRISm) is associated with features of and progression to obstructive lung disease.

Authors:  Spyridon Fortis; Alejandro Comellas; Victor Kim; Richard Casaburi; John E Hokanson; James D Crapo; Edwin K Silverman; Emily S Wan
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

View more
  2 in total

1.  First Maintenance Therapy for Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases.

Authors:  Chloe I Bloom; Jukka Montonen; Olaf Jöns; Elizabeth M Garry; Surya P Bhatt
Journal:  Pulm Ther       Date:  2022-01-10

2.  Prevalence of Chronic Obstructive Pulmonary Disease in an Urban Area. Changes in COPD Ten Years on.

Authors:  Elena García Castillo; Tamara Alonso Pérez; Adrián Peláez; Patricia Pérez González; Joan B Soriano; Julio Ancochea
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-09-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.